Phage derived lytic peptides, a secret weapon against Acinetobacter baumannii-An in silico approach
- PMID: 36405598
- PMCID: PMC9672511
- DOI: 10.3389/fmed.2022.1047752
Phage derived lytic peptides, a secret weapon against Acinetobacter baumannii-An in silico approach
Erratum in
-
Correction: Phage derived lytic peptides, a secret weapon against Acinetobacter baumannii-An in silico approach.Front Med (Lausanne). 2025 Jun 27;12:1642178. doi: 10.3389/fmed.2025.1642178. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40655107 Free PMC article.
Abstract
Acinetobacter baumannii is a bacterial pathogen that is commonly associated with hospital-acquired illnesses. Antimicrobial drug resistance in A. baumannii includes several penicillin classes, first and second-generation cephalosporins, cephamycins, most aminoglycosides, chloramphenicol, and tetracyclines. The recent rise in multidrug-resistant A. baumannii strains has resulted in an increase in pneumoniae associated with ventilators, urinary tract infections associated with the catheter, and bloodstream infections, all of which have increased complications in treatment, cost of treatment, and death. Small compounds known as antimicrobial peptides (AMPs) are known to have damaging effects on pathogenic bacteria. To determine their antimicrobial activity, AMPs are created from proteins acquired from various sources and evaluated in vitro. In the last phase of lytic cycle, bacteriophages release hydrolytic enzymes called endolysins that cleave the host's cell wall. Due to their superior potency and specificity compared to antibiotics, lysins are used as antibacterial agents. In the present study, different types of endolysin from phages of A. baumannii were selected based on an extensive literature survey. From the PhaLP database, the sequences of the selected lysins were retrieved in FASTA format and antimicrobial peptides were found among them. With the help of available bioinformatic tools, the anti-biofilm property, anti-fungal property, cell-penetrating property, and cellular toxicity of the antimicrobial peptides were determined. Out of the fourteen antimicrobial peptides found from the eight selected endolysins of A. baumannii specific phage, eight of them has anti-biofilm property, nine of them has anti-fungal property, five of them has cell-penetrating property and all of them are non-toxic.
Keywords: AMP; Acinetobacter baumannii; anti-fungal; antimicrobial peptides; biofilm; endolysin.
Copyright © 2022 Nandi, Yadav and Singh.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
In silico and in vitro comparative analysis of 79 Acinetobacter baumannii clinical isolates.Microbiol Spectr. 2025 Jul;13(7):e0284924. doi: 10.1128/spectrum.02849-24. Epub 2025 May 16. Microbiol Spectr. 2025. PMID: 40377313 Free PMC article.
-
Evolutionary dynamics and research hotspots of phage applications against Acinetobacter baumannii infections from the past to the new era.Front Microbiol. 2025 Jun 24;16:1606351. doi: 10.3389/fmicb.2025.1606351. eCollection 2025. Front Microbiol. 2025. PMID: 40630183 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
Cited by
-
Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies.Front Microbiol. 2024 Apr 5;15:1374466. doi: 10.3389/fmicb.2024.1374466. eCollection 2024. Front Microbiol. 2024. PMID: 38646632 Free PMC article. Review.
-
Making the leap from technique to treatment - genetic engineering is paving the way for more efficient phage therapy.Biochem Soc Trans. 2024 Jun 26;52(3):1373-1384. doi: 10.1042/BST20231289. Biochem Soc Trans. 2024. PMID: 38716972 Free PMC article. Review.
-
Novel MRSA-targeting phage MetB16: Genomic features, structural insights, and therapeutic applications.Turk J Biol. 2025 Feb 14;49(3):292-308. doi: 10.55730/1300-0152.2746. eCollection 2025. Turk J Biol. 2025. PMID: 40678418 Free PMC article.
-
Microbial- and Plant-Derived Bioactive Peptides and Their Applications against Foodborne Pathogens: Current Status and Future Prospects.Int J Microbiol. 2024 Apr 29;2024:9978033. doi: 10.1155/2024/9978033. eCollection 2024. Int J Microbiol. 2024. PMID: 38716460 Free PMC article. Review.
-
Characterization of holins, the membrane proteins of coliphage ASEC2201: a genomewide in silico approach.Front Microbiol. 2025 Jul 9;16:1550594. doi: 10.3389/fmicb.2025.1550594. eCollection 2025. Front Microbiol. 2025. PMID: 40703241 Free PMC article.
References
-
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. WHO Pathogens Priority list working group. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. (2018) 18:318–27. 10.1016/S1473-3099(17)30753-3 - DOI - PubMed
LinkOut - more resources
Full Text Sources